BioSpace News Archive

Innervace, a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry, announced today it has raised up to $40 million in Series A financing.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society (ISCoS) Annual Scientific Meeting on September 17, 2022.

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership with actress, singer-songwriter and advocate Lynda Carter Altman to accelerate diagnostics and treatments, including precision medicine approaches, for a deadly and difficult-to-treat form of blood cancer.

The latest research report indicates the global sterility testing market displayed an outstanding compound annual growth rate of 12.3 % over the forecast period of 2021.

The digital health market is likely to grow at a CAGR of 27.7% in the foreseeable years from 2022 to 2032.

Trauma, shock, stroke, sepsis, traumatic brain injury (TBI), and burst brain aneurysms are the most prevalent disorders linked to nervous system involvement, and their rising incidence is the main factor driving the neuro critical care market expansion.

Cervical cancer is a medical condition in which cells present in the lining of the cervix gradually develop into pre-cancerous mass of cells that ultimately turn into cancerous tumors.

Rise in the need for fulfilling the regulatory mandates by healthcare providers is projected to boost sales avenues in the global healthcare contract management software market during the forecast period from 2021 to 2031.

The liver disease treatment market is anticipated to chart an impressive growth trajectory over the forecast period from 2020 to 2030.

NuGen Medical Devices Inc. is pleased to announce, further to its press releases of July 22, 2022 and August 10, 2022, it has closed the second tranche of its previously announced non-brokered private placement through the issuance of 2,285,763 units at a price of $0.10 per Unit for gross proceeds of $228,576.30.